➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
McKinsey
Boehringer Ingelheim
Colorcon
Mallinckrodt

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

Litigation Details for Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc. (D. Del. 2013)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc. (D. Del. 2013)

Docket   Start Trial Date Filed 2013-08-30
Court District Court, D. Delaware Date Terminated 2016-01-11
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand None Referred To
Parties PAR PHARMACEUTICAL INC.
Patents 7,601,758; 7,619,004; 7,820,681; 7,906,519; 7,915,269; 7,935,731; 7,964,647; 7,964,648; 7,981,938; 8,093,296; 8,093,297; 8,093,298; 8,097,655; 8,415,395; 8,415,396; 8,440,721; 8,440,722
Attorneys Bradford C. Frese
Link to Docket External link to docket
Small Molecule Drugs cited in Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Takeda Pharmaceuticals USA Inc. v. Par Pharmaceutical Companies Inc. (D. Del. 2013)

Date Filed Document No. Description Snippet Link To Document
2014-10-09 106 infringement of U.S. Patent Nos. 7,619,004 (“the ’004 patent”); 7,601,758 (“the ’758 patent”); 7,820,681 (“…(“the ’681 patent”); 7,915,269 (“the ’269 patent”); 7,964,647 (“the ’647 patent”); 7,964,648 (“the ’648…648 patent”); 7,981,938 (“the ’938 patent”); 8,093,296 (“the ’296 patent”); 8,093,297 (“the ’297 patent8,097,655 (“the ’655 patent”); 8,415,395 (“the ’395 patent”); 8,415,396 (“the ’396 patent”); 8,440,721 (“the…“the ’721 patent”); and 8,440,722 (“the ’722 patent”) (collectively, “the Gout Patents”); will not infringe External link to document
2015-06-01 196 .S. Patent Nos. 7,619,004 ("the '004 patent"), 7,964,647 ("the '647 patent"…the '64 7 patent, claim 1 of the '938 patent, claims 1 and 13 of the '395 patent, and claim …,938 ("the '938 patent"), 8,415,395 ("the '395 patent"), and 8,415,396 (&…("the '396 patent") shall be construed consistent with the tenets of claim construction…construction required. Claim 1 of the '938 patent calls for administering 1.2 mgA oral colchicine External link to document
2014-09-04 66 Fourteen patents- U.S. Patent Nos. 7,619,004 ("the '004 patent"); 7,601,758 ("the…269 patent"); 7,964,647 ("the '647 patent"); 7,981,938 ("the '938 patent"…ex. 1 at~ 15) Five patents- U.S. Patent Nos. 7,906,519 ("the '519 patent"); 7,935,731 (…the '758 patent"); 7,820,681 ("the '681 patent"); 7,915,269 ("the '269…,296 ("the '296 patent"); 8,097,655 ("the '655 patent"); 8,415,395 (" External link to document
2014-09-04 90 Fourteen patents- U.S. Patent Nos. 7,619,004 ("the '004 patent"); 7,601,758 ("the…269 patent"); 7,964,647 ("the '647 patent"); 7,981,938 ("the '938 patent"…ex. 1 at~ 15) Five patents- U.S. Patent Nos. 7,906,519 ("the '519 patent"); 7,935,731 (…the '758 patent"); 7,820,681 ("the '681 patent"); 7,915,269 ("the '269…,296 ("the '296 patent"); 8,097,655 ("the '655 patent"); 8,415,395 (" External link to document
2014-09-04 91 G. United States Patent Number 7,601,758 (“the ‘758 Patent”), entitled “METHODS FOR CONCOMITANT…States Patent Nos. 7,906,519; 7,935,731; 8,093,298; 7,964,648; 8,093,297; 7,619,004; 7,601,758; 7,820,681… This is an action for patent infringement under the Food and Drug and Patent Laws of the United States… A. United Sates Patent Number 7,906,519 (“the ‘519 Patent”), entitled “METHODS FOR CONCOMITANT… B. United States Patent Number 7,935,731 (“the ‘731 Patent”), entitled “METHODS FOR CONCOMITANT External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Mallinckrodt
Johnson and Johnson
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.